Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Pifeltro | doravirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Skyrizi | risankizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Venclexta in combo Rituximab | Venetoclax | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
Botox | onabotulinumtoxinA | Migraine, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Cresemba | isavuconazole | Treatment of invasive aspergillosis and mucormycosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Cimzia | certolizumab pegol | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Fulphila | pegfilgrastim | Febrile neutropenia in non-myeloid malignancies | N/A | Complete | ||
Verzenio | Abemaciclib | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Alunbrig | Brigatinib | NSCLC | Do not reimburse | Complete | ||
Keytruda | Pembrolizumab | Melanoma Adjuvant Treatment | Reimburse with clinical criteria and/or conditions | Complete |